Summit Therapeutics Inc. (SMMT) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Cambridge, MA, United States. The current CEO is Robert W. Duggan.
SMMT has IPO date of 2015-03-05, 159 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $15.52B.
Summit Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines to treat infectious diseases in the United States and Latin America. The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic currently in Phase III clinical trials for Clostridioides difficile infection (CDI). Summit's pipeline also includes SMT-738, designed to address multidrug-resistant infections such as carbapenem-resistant Enterobacteriaceae, and the DDS-04 series for treating Enterobacteriaceae infections. Founded in 2003 and headquartered in Cambridge, Massachusetts, the company is advancing its clinical programs to address critical unmet needs in infectious disease treatment.
